Home Biosimilar Antibodies Immunology & Inflammation Interleukins Risankizumab (anti-IL-23) For research use only.
Not for use in humans.

Risankizumab (anti-IL-23)

Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Risankizumab (anti-IL-23)

Click to purchase the isotype control of Risankizumab (anti-IL-23)

1 Customer Review

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 15.71mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective Interleukins Inhibitors

Biological Activity

Description Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Product Details

CAS No. 1612838-76-2
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Risankizumab (anti-IL-23)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) supplier | purchase Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) cost | Risankizumab (anti-IL-23) manufacturer | order Risankizumab (anti-IL-23) | Risankizumab (anti-IL-23) distributor